We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksELTA.L Regulatory News (ELTA)

  • There is currently no data for ELTA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Electra Partners announces the sale of Vidal Group

7 Oct 2016 07:05

RNS Number : 9394L
Electra Private Equity PLC
07 October 2016
 

PRESS RELEASE

7 October 2016

 

 

 

Electra Partners announces the sale of Vidal Group

 

Electra Partners is pleased to announce that its portfolio company AXIO Group ("AXIO") has received a binding offer from M3, Inc. to purchase Vidal Group ("Vidal"), a leading European provider of reference drug information for healthcare professionals, for €100 million. The proposed transaction, which remains subject to certain conditions including consultation with the relevant works council in France and regulatory approvals, would be the fourth major realisation from AXIO's portfolio.

 

Based on today's exchange rates, Electra Private Equity PLC ("Electra") would receive proceeds from AXIO of£55 million, an uplift of £17 million on the valuation of Electra's investment at 31 March 2016 and equivalent to an increase in its NAV of 35 pence per share. The sale of Vidal would increase the total cash proceeds received by Electra from its investment in AXIO to almost £250 million, or 2.8x original cost, and the total return, including Electra's investment in the remaining AXIO businesses, to 4.0x original cost.

 

Vidal is a leading European healthcare informatics and information systems company. The company provides hospitals, primary care physicians, pharmacists and patients across Europe with access to up-to-date drug databases and related treatment-based information, and so brings drug intelligence and clinical decision support tools directly to the point of care.

 

Alex Cooper-Evans, Partner at Electra Partners, said:

 

"The proposed sale of Vidal is another example of the successful implementation of our strategy for AXIO. We started in 2013 with a complex portfolio of disparate assets which we have transformed by putting in place the right long-term strategy and delivering with operational improvement, growth investment and M&A. This transformation has resulted in AXIO's businesses becoming highly attractive to strategic buyers.

 

"The AXIO investment is performing well: the sale of Vidal would take the total return to 4.0x investment cost, including cash proceeds of 2.8x investment cost. The remaining businesses in the AXIO portfolio generated EBITDA of £16 million in 2015, a level which has more than doubled over the course of our ownership. We will continue to drive performance across these businesses through the ongoing application of our active ownership approach."

 

Alex Fortescue, Alex Cooper-Evans and Sarah Williams are responsible for the investment in AXIO Group.

 

Electra has seen a high level of investment activity since September 2015. Including today's announcement this period has seen realisations or agreements to sell of nearly £1 billion and new investments of over £200 million. Realisations announced since September 2015 include the exits of Daler-Rowney, Elian, Kalle, MIMS and Zensar Technologies, the partial realisations of Allflex, Hollywood Bowl and Premier Asset Management, and the proceeds from the refinancing of the Park Resorts Group at the time of its merger with Parkdean Holidays. New investments include the buyouts of Photobox Group and Retirement Bridge Group and investments in two CLOs.

 

Electra Partners refers to Electra Partners LLP acting on behalf of its client Electra Private Equity PLC.

 

Ends

 

 

For further information please contact:

Andrew Honnor, Matthew Goodman, Matthieu Roussellier, Greenbrook Communications +44 (0)20 7952 2000

Nicholas Board and Andrew Kenny, Electra Partners +44 (0)20 7306 3902

 

 

 

 

Note to Editors:

About Electra Partners LLP

Electra Partners is an independent private equity fund manager with over 25 years' experience. During this time it has invested in excess of £4.7 billion in over 200 deals. As at 31 March 2016, the firm had funds under management of£2 billion.

 

Electra Partners' flexible investment strategy allows it to invest broadly across the private equity market with a particular focus on Buyouts and Co-investments, Secondaries and Debt.

 

The firm's major client is Electra Private Equity PLC ("Electra"), a private equity investment trust which has been listed on the London Stock Exchange since 1976. Electra's long-term investment performance has been consistently superior to private equity and other benchmarks. Over the ten years to 31 March 2016, Electra has seen diluted NAV per share growth of 228%. This is more than seven times the NAV per share return of the Morningstar Private Equity Index (ex. Electra). It is also equivalent to a ten-year annualised return of 13%, in the upper part of Electra's target range of 10-15% over the long-term.

 

For further information please visit www.electrapartners.com.

 

Electra Partners LLP is authorised and regulated by the Financial Conduct Authority.

 

About AXIO Group

AXIO Group manages a portfolio of market-leading information businesses providing critical, and often industry-standard, information and tools. Operating in 12 countries worldwide, the group's brands include Vidal in the healthcare sector, TechInsights in the intellectual property sector, OAG in the global aviation sector and RISI in the forest products sector.

 

For further information, please visit www.axiogroup.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMFBFTMBTMBFF
Date   Source Headline
16th Jun 20217:00 amRNSTrading update and company announcement
14th Jun 202110:58 amRNSHalf-year Report
1st Jun 20218:00 amRNSTotal Voting Rights
28th May 202110:39 amRNSAnalyst Note produced by HSBC Global Research
26th May 202110:01 amRNSEdison issues update on Electra Private Equity
24th May 20212:26 pmRNSReplacement: Holding(s) in Company
24th May 20211:41 pmRNSHolding(s) in Company
24th May 20211:27 pmRNSDirector/PDMR Shareholding
24th May 20211:27 pmRNSDirector/PDMR Shareholding
24th May 20217:00 amRNSIssue of Equity
21st May 20211:00 pmRNS2021 Half Year Report Supplementary Information
21st May 20217:00 amRNSHalf-year Report
19th Apr 20217:00 amRNSEdison issues update on Electra Private Equity
15th Apr 20217:00 amRNSDisposal of Sentinel and Portfolio Trading Update
13th Apr 20214:41 pmRNSSecond Price Monitoring Extn
13th Apr 20214:35 pmRNSPrice Monitoring Extension
22nd Mar 20213:07 pmRNSHolding(s) in Company
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:35 pmRNSPrice Monitoring Extension
5th Mar 20214:49 pmRNSDirector/PDMR Shareholding
4th Mar 20215:03 pmRNSDirector/PDMR Shareholding
4th Mar 202110:39 amRNSAGM Statement
3rd Mar 20215:21 pmRNSDirector/PDMR Shareholding
24th Feb 20214:45 pmRNSResult of AGM
24th Feb 20217:00 amRNSAGM Statement
26th Jan 20213:10 pmRNSAnnual Report and Notice of Annual General Meeting
17th Dec 20204:41 pmRNSEdison initiates on Electra Private Equity (ELTA)
17th Dec 20208:51 amEQSElectra Private Equity (ELTA): Innovating, restructuring and realising
16th Dec 202012:10 pmRNSEdison Investment Research note
9th Dec 20207:00 amRNSFinal Results
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:36 pmRNSPrice Monitoring Extension
13th Nov 202010:33 amRNSPress speculation re Hotter Shoes
27th Aug 202011:37 amRNSConfirmation of Reduction of Capital
27th Aug 20207:00 amRNSExpiry of Hotter Shoes CVA Challenge Period
26th Aug 20209:08 amRNSHolding(s) in Company
29th Jul 202011:29 amRNSDirector/PDMR Shareholding
29th Jul 20207:00 amRNSCompany update including outcome of Hotter CVA
19th Jun 20202:41 pmRNSHotter Shoes Restructure
19th Jun 20201:33 pmRNSResult of General Meeting
12th Jun 20202:44 pmRNSHalf-year Report
22nd May 20205:02 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSNotice of General Meeting re reduction of capital
21st May 20207:00 amRNSHalf-year Report
1st May 20202:14 pmRNSDisclosure of rights attached to equity shares
20th Mar 20207:00 amRNSUpdate in respect of the COVID-19 situation
18th Mar 20204:43 pmRNSSecond Price Monitoring Extn
18th Mar 20204:39 pmRNSPrice Monitoring Extension
17th Mar 202011:47 amRNSHolding(s) in Company
16th Mar 202012:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.